Prenatal exposure to perfluoroalkyl acids and allergic diseases in early childhood

• DOI: 10.1016/j.envint.2014.01.007
• Publication Date: 2014-01-30T19:33:57Z
• Authors: Emiko Okada; Seiko Sasaki; Ikuko Kashino; Hideyuki Matsuura; Chihiro Miyashita; Sumitaka Kobayashi; Kumiko Itoh; Tamiko Ikeno; Akiko Tamakoshi; Reiko Kishi
• Keywords: Adult; Male; Fluorocarbons; Allergic diseases; Eczema; Infant; Perfluoroalkyl acids; 498; 3. Good health; 03 medical and health sciences; Perfluorotridecanoic acid; Sex Factors; 0302 clinical medicine; Pregnancy; Tandem Mass Spectrometry; Prenatal exposure; Child, Preschool; Prenatal Exposure Delayed Effects; Hypersensitivity; Odds Ratio; Humans; Female; Caprylates

Perfluoroalkyl acids (PFAAs) are persistent organic pollutants that are detected in humans worldwide. Laboratory animal studies have shown that PFAAs are associated with immunotoxic effects. However, epidemiological studies investigating the role of PFAAs, in particular PFAAs with longer chains than perfluorooctanoic acid, are scarce. We investigated associations between prenatal exposure to PFAAs, including long-chain compounds, and infant allergic diseases at 12 and 24months in a large study population. The participants included mothers and their infants who enrolled in the Hokkaido Study on Environment and Children's Health 2003-2009. Eleven PFAAs were measured in maternal plasma taken at 28-32weeks of gestation using ultra-performance liquid chromatography coupled to triple quadrupole tandem mass spectrometry. Characteristics of participants and information on infant allergic diseases were obtained from self-administered questionnaires and medical records. At 24months, the adjusted odds ratio (OR) (first vs. fourth quartiles) for eczema in association with higher maternal perfluorotridecanoic acid (PFTrDA) levels was 0.62 (95% confidence interval (CI) 0.45, 0.86). After stratification by gender, the adjusted ORs in female infants from mothers with higher maternal perfluoroundecanoic acid (PFUnDA) and PFTrDA levels were also statistically significant (PFUnDA: OR=0.50; 95% CI, 0.30, 0.81; PFTrDA: OR=0.39; 95% CI, 0.23, 0.64). Our findings suggest that lower prenatal exposure to PFTrDA may decrease the risk of developing eczema in early childhood, only in female infants.